[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100208734":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":27,"responsibleParty":51,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":75,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"sensitive group; resistant group",null,"sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration.\n\nresistant patients were defined as patients reached PD after first month administration and first three months administration",[13],{"name":14,"affiliation":15,"role":16},"Min Huang, Professor","school of pharmaceutical sciences , SunYat-senU","STUDY_CHAIR",[18,24],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"shaoxing guan, PHD","CONTACT","+86 13129351756","+8613129351756","guanshx6@mail.sysu.edu.cn",{"name":14,"role":20,"phone":25,"phoneExt":10,"email":26},"+86 020 87331409-101","huangmin@mail.sysu.edu.cn",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Cancer Center, Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":37,"coordinates":38},"Point",[39,40],113.25,23.11667,{"lat":40,"lon":39},[43,47,49],{"name":44,"role":20,"phone":45,"phoneExt":10,"email":46},"Shuang Xin, PHD","+86 13580479553","xshuang@mail2.sysu.edu.cn",{"name":19,"role":20,"phone":21,"phoneExt":48,"email":23},"13129351756",{"name":14,"role":50,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Guan shaoxing, PHD","PHD","100208734","a-retrospective-study-of-egfr-tkisgefitinib-erlotinib-and-osimertinib-in-nsclc-patients-treatment-100208734",false,"NCT01994057","A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment","Retrospective Study Based on Somatic Mutations, Genetic Polymorphisms and Metabolomics Related to Individual Variations of Drug Effect and Adverse Drug Reaction of EGFR-TKIs,Gefitinib and Erlotinib in Non-small Cell Lung Cancer Treatment.","Inclusion Criteria:\n\nThe main patient entry criteria included: age≥ 18 years ; histologically and cytologically proved NSCLC; Eastern cooperative oncology group performance status (ECOG PS)≤2; adequate hematological , renal, and hepatic functions. Exclusion Criteria:\n\nuncontrolled systemic disease ,any evidence of clinically active interstitial lung diseases, and other chemotherapy at the time of inclusion. The protocol was approved by the Ethical Committee of Cancer Center of Sun Yat-Sen University (CCSU), and written informed consent was obtained form each patient.","ALL","18 Years","85 Years",{"count":65,"type":66},1000,"ESTIMATED","OBSERVATIONAL","For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and erlotinib administration based on EGFR-TKIs sensitive mutations.From clinical points of view ,individual differences often occur between different patients, leading diverse effect in ADR and drug effect.Meanwhile ,the drug effect and adverse drug reaction was significantly influenced by the pharmacokinetic factors and pharmacodynamic factors.In this research ,we try to establish a more sensitive method to detect sensitive mutations in plasma and discover the correlation between somatic and germline mutations , trough concentration and EGFR-TKI drug effect, the association between ADME-associated SNP ,trough concentration and EGFR-TKI adverse effect .Furthermore, in vivo and in vitro research is also crucial for rational explanation for these clinical phenomenon.",[70,71,72,73,74],"Non-small Cell Lung Cancer (NSCLC)","EGFR-TKI Resistant Mutation","EGFR-TKI Sensitizing Mutation","Germline Mutations","Somatic Mutation",[76,77,78,79,80],"Non-small cell lung cancer (NSCLC);","EGFR-TKI;","Pharmacogenetics;","Precision medicine","somatic mutations ,germline mutations;","2023-04-10",{"date":83,"type":84},"2023-04-12","ACTUAL",{"date":86,"type":10},"2012-09",{"date":88,"type":66},"2026-12",{"name":5,"class":6},1]